




Supplementary Figure 1. Gating strategy to identify naïve, IgM memory and IgG memory B cells before rituximab therapy (A) and 12 months after treatment initiation (B). Peripheral blood B cell frequencies from all live cells in the lymphocyte gate and are shown in (C). Panel A and B were generated with data from the same patient.




Supplementary Figure 2. IgH chain gene variable (V) repertoires in single cell sorted CD19⁺CD27⁺IgM⁺, CD19⁺CD27⁺IgM⁺ and CD19⁺CD27⁺IgG⁺ B cells, respectively. Samples were analyzed before and 12 months after rituximab and placebo (normal saline solution) therapy. Clonally expanded sequences were counted as one sequence. The numbers in circles indicate the number of individual sequences per patient.



Supplementary Figure 3. IgH diversity (D) region repertoires in single cell sorted CD19⁺CD27IgM⁺, CD19⁺CD27IgM⁺ and CD19⁺CD27⁺IgG⁺ B cells, respectively. Samples were analyzed before and 12 months after rituximab and placebo (normal saline solution) therapy. Clonally expanded sequences were counted as one sequence. The numbers in circles indicate the number of individual sequences per patient.



Supplementary Figure 4. IgH chain joining (J) regions repertoires in single cell sorted CD19⁺CD27⁺IgM⁺, CD19⁺CD27⁺IgM⁺ and CD19⁺CD27⁺IgG⁺ B cells, respectively. Samples were analyzed before and 12 months after rituximab and placebo (normal saline solution) therapy. Clonally expanded sequences were counted as one sequence. The numbers in circles indicate the number of individual sequences per patient.



Supplementary Table 1. Frequency of expanded sequences in the memory compartment of all patients before and after therapy are depicted as frequency of expanded sequences divided by the total sequence count for each patient.

Patient Subgroup	Patient	Memory compartment	Before Vs. after therapy	Frequency of exp. seq. (%)
Placebo	P8	IgM	after	7/45 (15.6%)
Placebo	P8	IgM	after	2/45 (4.4%)
Placebo	P8	IgM	after	2/45 (4.4%)
Placebo	P8	IgM	after	2/45 (4.4%)
Placebo	P8	IgM	after	2/45 (4.4%)
Placebo	P8	IgM	after	2/45 (4.4%)
Placebo	P8	IgM	before	12/31 (38.7%)
Placebo	P8	IgM	before	3/31 (9.7%)
Placebo	P8	IgG	before	2/37 (5.4%)
Placebo	P8	IgG	before	3/37 (8.1%)
Placebo	P8	IgG	after	3/31 (9.7%)
Placebo	P9	IgM	before	31/43 (72.1%)
Placebo	P9	IgM	before	2/43 (4.7%)
Placebo	P9	IgM	after	45/67 (67.2%)
Placebo	P9	IgM	after	3/67 (4.5%)
Placebo	P9	IgG	after	20/60 (33.3%)
Placebo	P9	IgG	after	2/60 (3.3%)
Placebo	P9	IgG	after	2/60 (3.3%)
Placebo	P9	IgG	after	2/60 (3.3%)
Placebo	P11	IgM	before	12/13 (92.3%)
Placebo	P11	IgM	after	8/24 (33.3%)
Placebo	P11	IgM	after	4/24 (16.7%)

Placebo	P11	IgM	after	2/24 (8.3%)
Placebo	P11	IgM	after	2/24 (8.3%)
Placebo	P13	IgM	after	2/16 (12.5%)
Placebo	P16	IgM	after	3/29 (10.3%)
Placebo	P16	IgM	after	2/29 (6.9%)
Placebo	P21	IgM	before	4/57 (7.0%)
Placebo	P21	IgM	before	2/57 (3.5%)
Responder	P3	IgM	after	2/37 (5.4%)
Responder	P3	IgM	after	2/37 (5.4%)
Responder	P3	IgG	after	3/16 (18.8%)
Responder	P14	IgM	before	6/49 (12.2%)
Responder	P14	IgM	before	2/49 (4.1%)
Responder	P14	IgM	before	2/49 (4.1%)
Responder	P14	IgG	after	2/9 (22.2%)
Responder	P27	IgM	before	7/44 (15.9%)
Responder	P27	IgM	before	4/44 (9.1%)
Non-responder	P5	IgG	after	2/44 (4.5%)
Non-responder	P5	IgG	before	2/38 (5.3%)
Non-responder	P5	IgM	after	5/20 (25%)
Non-responder	P5	IgM	after	4/20 (20%)
Non-responder	P5	IgM	after	4/20 (20%)
Non-responder	P5	IgM	before	19/78 (24.4%)
Non-responder	P5	IgM	before	2/78 (2.6%)
Non-responder	P6	IgM	before	2/32 (6.3%)
Non-responder	P6	IgM	before	2/32 (6.3%)
Non-responder	P6	IgM	before	2/32 (6.3%)

Non-responder	P6	IgM	after	3/31 (9.7%)
Non-responder	P10	IgG	before	2/35 (5.7%)
Non-responder	P10	IgM	after	2/53 (3.8%)
Non-responder	P10	IgM	before	3/58 (5.2%)
Non-responder	P10	IgM	before	2/58 (3.4%)
Non-responder	P10	IgM	before	24/58 (41.4%)
Non-responder	P12	IgM	before	3/43 (7.0%)
Non-responder	P12	IgM	before	2/43 (4.7%)
Non-responder	P17	IgM	before	2/74 (2.7%)
Non-responder	P17	IgM	before	2/74 (2.7%)
Non-responder	P17	IgM	before	10/74 (13.5%)
Non-responder	P17	IgM	before	2/74 (2.7%)
Non-responder	P17	IgG	after	2/33 (6.1%)
Non-responder	P18	IgG	after	2/23 (8.7%)
Non-responder	P22	IgG	after	2/3 (66.7%)
Non-responder	P22	IgM	before	2/30 (6.7%)
Non-responder	P22	IgM	after	2/25 (8.0%)
Non-responder	P23	IgM	after	6/43 (14.0%)
Non-responder	P23	IgM	after	2/43 (4.7%)
Non-responder	P23	IgM	before	2/64 (3.1%)
Non-responder	P23	IgM	before	2/64 (3.1%)
Non-responder	P23	IgM	before	2/64 (3.1%)
Non-responder	P23	IgM	before	2/64 (3.1%)
Non-responder	P23	IgM	before	1/64 (1.5%)
Non-responder	P26	IgM	after	4/38 (10.5%)
Non-responder	P26	IgM	after	2/38 (5.3%)

Non-responder	P26	IgM	after	2/38 (5.3%)
---------------	-----	-----	-------	-------------

4/45 (8.8%)	<i>IGHV3-7*01</i>	<i>IGHJ4*02</i>	<i>IGHD5-12*01</i>	75	1	24	8	51	1	24	3	114	9
1/45 (2.2%)	<i>IGHV1-58*01</i>	<i>IGHJ5*02</i>	<i>IGHD3-10*01</i>	75	54	24	14	51	3	24	6	114	34
1/45 (2.2%)	<i>IGHV3-53*02</i>	<i>IGHJ6*02</i>	<i>IGHD1-26*01</i>	75	17	24	1	51	4	21	2	114	4
1/45 (2.2%)	<i>IGHV1-58*01</i>	<i>IGHJ5*02</i>	<i>IGHD3-10*01</i>	75	51	24	16	51	1	24	0	109	28
1/45 (2.2%)	<i>IGHV3-7*01</i>	<i>IGHJ4*02</i>	<i>IGHD3-16*01</i>	75	57	24	21	51	20	24	5	110	18
1/45 (2.2%)	<i>IGHV1-58*01</i>	<i>IGHJ5*02</i>	<i>IGHD3-10*01</i>	75	59	24	10	51	1	24	2	114	27
1/45 (2.2%)	<i>IGHV3-7*01</i>	<i>IGHJ5*01</i>	<i>IGHD2-2*01</i>	75	6	24	8	51	5	24	5	114	16
1/45 (2.2%)	<i>IGHV3-7*01</i>	<i>IGHJ5*01</i>	<i>IGHD3-10*01</i>	75	6	24	11	51	7	24	6	67	41
1/45 (2.2%)	<i>IGHV1-58*01</i>	<i>IGHJ5*02</i>	<i>IGHD3-10*01</i>	75	59	24	20	51	1	24	2	114	9
1/45 (2.2%)	<i>IGHV3-74*03</i>	<i>IGHJ4*02</i>	<i>IGHD6-6*01</i>	75	0	24	9	51	1	24	7	114	9
1/45 (2.2%)	<i>IGHV1-58*01</i>	<i>IGHJ5*02</i>	<i>IGHD3-10*01</i>	75	4	24	0	51	1	24	0	114	7

Supplementary Table 3. Individual VH, DH, JH sequences and mutations in IgM memory B cells of patient 27 after therapy.

Frequency of seq. (%)	V-gene allele	J-gene allele	D-gene allele	FWR1 length bp	CDR1 length bp	FWR1 mutations	CDR1 mutations	FWR2 length bp	CDR2 length bp	FWR3 mutations	Sequenc
1/52 (1.9%)	IGHV3-15*01	IGHJ6*02	IGHD3-10*01	75	1	24	0	51	0	24	0
1/52 (1.9%)	IGHV4-61*02	IGHJ5*02	IGHD2-15*01	75	1	27	0	51	0	21	0
1/52 (1.9%)	IGHV5-51*03	IGHJ5*02	IGHD6-13*01	75	5	24	5	51	1	24	8
1/52 (1.9%)	IGHV4-4*02	IGHJ4*02	IGHD1-26*01	75	0	24	0	51	0	30	0
1/52 (1.9%)	IGHV3-53*01	IGHJ4*02	IGHD6-13*01	75	0	24	0	51	0	21	0
1/52 (1.9%)	IGHV1-3*01	IGHJ4*02	IGHD6-6*01	75	0	24	0	51	1	30	2
1/52 (1.9%)	IGHV4-61*02	IGHJ3*02	IGHD6-6*01	75	1	24	2	51	0	21	0

